Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07844772

Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis

Sponsor: Istanbul Training and Research Hospital

View on ClinicalTrials.gov

Summary

The goal of this observational study is to better understand whether blood levels of Substance P are related to pain, itching, altered pain sensations, central sensitization, psoriasis severity, and quality of life in adults with chronic plaque psoriasis. The main questions this study aims to answer are: Are serum Substance P levels associated with neuropathic pain features, central sensitization, psoriasis severity, pain, itching, and quality of life? Do serum Substance P levels and these clinical features differ among patients receiving different psoriasis treatments? Researchers will compare three groups of patients: those receiving IL-17 inhibitor treatment, those receiving conventional systemic treatment with methotrexate or acitretin, and those receiving topical treatment only or no current treatment. Participants will: Have their psoriasis severity assessed and complete questionnaires about pain, itching, central sensitization, and quality of life. Undergo a neurological examination. Participants who report pain will also be evaluated for neuropathic pain features using the DN4 questionnaire. Provide a blood sample for measurement of serum Substance P and routine laboratory tests. Undergo electromyography and nerve conduction studies if peripheral neuropathy is suspected during the neurological evaluation. No treatment will be assigned or changed as part of this study.

Official title: Evaluation of the Association of Serum Substance P Levels With Neuropathic Pain, Central Sensitization, Disease Severity, and Quality of Life Across Different Treatment Groups in Patients With Chronic Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

100

Start Date

2026-06-11

Completion Date

2027-01

Last Updated

2026-09-28

Healthy Volunteers

No

Interventions

BIOLOGICAL

IL-17 Inhibitor Therapy

Exposure to IL-17 inhibitor therapy prescribed as part of routine clinical care for chronic plaque psoriasis. Treatment is not assigned, initiated, or modified by the study. Participants are classified according to their current treatment at the time of study assessment.

DRUG

Conventional Systemic Therapy

Exposure to conventional systemic therapy with methotrexate or acitretin prescribed as part of routine clinical care for chronic plaque psoriasis. Treatment is not assigned, initiated, or modified by the study.

Locations (1)

Istanbul Training and Research Hospital

Istanbul, Istanbul, Turkey (Türkiye)